Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Mechanism of Action
Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1.
Research Summary
STEP trials demonstrated average weight loss of 15-17% body weight over 68 weeks. SELECT trial showed 20% reduction in major cardiovascular events. Proven efficacy for glycemic control in type 2 diabetes with A1C reductions of 1.5-2%.
Research Protocols
Note: Prescribed doses per FDA labeling
Common Doses
- •0.25mg weekly (starting)
- •0.5mg weekly
- •1mg weekly
- •2.4mg weekly (Wegovy max)
Duration
Long-term / chronic use
Administration
Subcutaneous injection weekly, or oral (Rybelsus)
Side Effects & Considerations
- •Nausea (most common, usually transient)
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Risk of pancreatitis
- •Thyroid C-cell tumor risk (boxed warning)
- •Gallbladder issues
References
Want updates on Semaglutide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.